{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:56:33Z","timestamp":1778763393213,"version":"3.51.4"},"reference-count":52,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702674"],"award-info":[{"award-number":["81702674"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in various types of tumors and functions as an oncogene; it could also be a potential target in tumor therapy. Meanwhile, the high mortality of pancreatic adenocarcinoma (PAAD) largely depends on the limited effectiveness of therapy. Based on the promising potential of PTTG1 in cancer treatment, we explored the influence of PTTG1 on the treatment of PAAD in this study. The Cancer Genome Atlas Program (TCGA) data showed that higher expression of PTTG1 was associated with higher clinical stages and worse prognosis of pancreatic cancer. In addition, the CCK-8 assay showed that the IC50 of gemcitabine and 5-fluorouracil (5-FU) was increased in BxPC-3-PTTG1high and MIA PaCa-2-PTTG1high cells. The TIDE algorithm indicated that the immune checkpoint blockades\u2019 (ICBs) efficiency is poor in the PTTG1 high group. Furthermore, we found that the efficiency of OAd5 was enhanced in BxPC-3-PTTG1high and MIA PaCa-2-PTTG1high cells and poor in BxPC-3-PTTG1low and MIA PaCa-2-PTTG1low cells. We used the OAd5 expressing GFP for transduction. As a result, the fluorescence intensity was enhanced in BxPC-3-PTTG1high and MIA PaCa-2-PTTG1high cells and decreased in BxPC-3-PTTG1low and MIA PaCa-2-PTTG1low cells 24 h after OAd5 transduction. The fluorescence intensity indicated that PTTG1 increased OAd5 entry. The flow cytometry assay showed that OAd5 receptor CXADR expression was enhanced by PTTG1. PTTG1 failed to further enhance OAd5 transduction in the case of CXADR knockdown. In summary, PTTG1 enhanced OAd5 transduction into pancreatic cancer cells by increasing CXADR expression on the cell surface.<\/jats:p>","DOI":"10.3390\/v15051153","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T04:29:01Z","timestamp":1683779341000},"page":"1153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PTTG1 Enhances Oncolytic Adenovirus 5 Entry into Pancreatic Adenocarcinoma Cells by Increasing CXADR Expression"],"prefix":"10.3390","volume":"15","author":[{"given":"Lu","family":"Long","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2830-4810","authenticated-orcid":false,"given":"Jian","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1073\/pnas.1318124111","article-title":"Pttg1\/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis","volume":"111","author":"Hatcher","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1210\/er.2006-0042","article-title":"Pituitary Tumor-Transforming Gene: Physiology and Implications for Tumorigenesis","volume":"28","author":"Vlotides","year":"2007","journal-title":"Endocr. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bulcan.2020.11.022","article-title":"The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1","volume":"108","author":"Huang","year":"2021","journal-title":"Bull. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129221","DOI":"10.1016\/j.chemosphere.2020.129221","article-title":"Bisphenol A promotes breast cancer cell proliferation by driving miR-381-3p-PTTG1-dependent cell cycle progression","volume":"268","author":"Deng","year":"2021","journal-title":"Chemosphere"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/hep.21137","article-title":"Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo","volume":"43","author":"Yoo","year":"2006","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"112002","DOI":"10.1016\/j.yexcr.2020.112002","article-title":"aarF domain containing kinase 5 gene promotes invasion and migration of lung cancer cells through ADCK5-SOX9-PTTG1 pathway","volume":"392","author":"Qiu","year":"2020","journal-title":"Exp. Cell Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Teveroni, E., Di Nicuolo, F., Bianchetti, G., Epstein, A.L., Grande, G., Maulucci, G., De Spirito, M., Pontecorvi, A., Milardi, D., and Mancini, F. (2021). Nuclear Localization of PTTG1 Promotes Migration and Invasion of Seminoma Tumor through Activation of MMP-2. Cancers, 13.","DOI":"10.3390\/cancers13020212"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s10020-020-00161-7","article-title":"Estrogen-regulated PTTG1 promotes breast cancer progression by regulating cyclin kinase expression","volume":"26","author":"Meng","year":"2020","journal-title":"Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12032-020-01398-2","article-title":"Suppression of PTTG1 inhibits cell angiogenesis, migration and invasion in glioma cells","volume":"37","author":"Cui","year":"2020","journal-title":"Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3892\/mmr.2022.12664","article-title":"miR-374c-5p regulates PTTG1 and inhibits cell growth and me-tastasis in hepatocellular carcinoma by regulating epithelial-mesenchymal transition","volume":"25","author":"Yang","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JP9.0000000000000029","article-title":"Development of microRNA-based therapy for pancreatic cancer","volume":"2","author":"Fesler","year":"2019","journal-title":"J. Pancreatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ctrv.2019.06.005","article-title":"Checkpoint inhibitors in pancreatic cancer","volume":"78","author":"Henriksen","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Akhuba, L., Tigai, Z., and Shek, D. (2022). Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123196"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2022","journal-title":"Trends Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Duan, S., Wang, S., Qiao, L., Yu, X., Wang, N., Chen, L., Zhang, X., Zhao, X., Liu, H., and Wang, T. (2023). Oncolytic Virus-Driven Biotherapies from Bench to Bedside. Small, e2206948.","DOI":"10.1002\/smll.202206948"},{"key":"ref_23","first-page":"597","article-title":"A review of 65 years of human adenovirus seroprevalence. Expert Rev","volume":"18","author":"Mennechet","year":"2019","journal-title":"Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Oronsky, B., Gastman, B., Conley, A.P., Reid, C., Caroen, S., and Reid, T. (2022). Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot. Cancers, 14.","DOI":"10.3390\/cancers14194701"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.003087-0","article-title":"Adenoviruses: Update on structure and function","volume":"90","author":"Russell","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"119594","DOI":"10.1016\/j.lfs.2021.119594","article-title":"PTTG1 knockdown en-hances radiation-induced antitumour immunity in lung adenocarcinoma","volume":"277","author":"Chen","year":"2021","journal-title":"Life Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/07853890.2021.2011956","article-title":"Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a bi-omarker for predicting immunotherapy response","volume":"54","author":"Tian","year":"2022","journal-title":"Ann. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s12325-021-01729-3","article-title":"CDC20 and PTTG1 are Important Biomarkers and Potential Therapeutic Targets for Metastatic Prostate Cancer","volume":"38","author":"Dai","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/COC.0000000000000193","article-title":"Eligibility of Metastatic Pancreatic Cancer Pa-tients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX","volume":"40","author":"Peixoto","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17588359211045861","DOI":"10.1177\/17588359211045861","article-title":"Updates on adjuvant and neoadjuvant treatment strategies for surgi-cally resectable and borderline resectable pancreatic ductal adenocarcinoma","volume":"13","author":"Iyengar","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","article-title":"A phase II study of modified FOLFIRINOX for chemotherapy-na\u00efve patients with metastatic pancreatic cancer","volume":"81","author":"Ozaka","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40880-019-0367-7","article-title":"The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer","volume":"39","author":"Wang","year":"2019","journal-title":"Cancer Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","article-title":"Immuno-oncology drug development goes global","volume":"18","author":"Yu","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1038\/s41467-020-17011-z","article-title":"Oncolytic virus-derived type I interferon restricts CAR T cell therapy","volume":"11","author":"Evgin","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Rep-lication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cas.13228","article-title":"Recent advances in genetic modification of adenovirus vectors for cancer treatment","volume":"108","author":"Yamamoto","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.07.006","article-title":"Advances in oncolytic adenovirus therapy for pancreatic cancer","volume":"434","author":"Nattress","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1128\/JVI.73.7.5333-5344.1999","article-title":"p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication","volume":"73","author":"Harada","year":"1999","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"Johnson","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/nbt887","article-title":"E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models","volume":"21","author":"Wang","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1078-0432.CCR-09-1960","article-title":"Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers","volume":"16","author":"Oberg","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/1535-7163.MCT-17-0671","article-title":"The Novel Oncolytic Adenoviral Mutant Ad5-3Delta-A20T Retargeted to alphavbeta6 Integrins Efficiently Eliminates Pancreatic Cancer Cells","volume":"17","author":"Man","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Mach, N., Gao, J., Schaffarczyk, L., Janz, S., Ehrke-Schulz, E., Dittmar, T., Ehrhardt, A., and Zhang, W. (2020). Spectrum-Wide Exploration of Human Adenoviruses for Breast Cancer Therapy. Cancers, 12.","DOI":"10.3390\/cancers12061403"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/cts.12413","article-title":"PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines","volume":"9","author":"Nakachi","year":"2016","journal-title":"Clin. Transl. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1210\/clinem\/dgac496","article-title":"Aspirin Mediates Its Antitumoral Effect Through Inhibiting PTTG1 in Pituitary Adenoma","volume":"107","author":"Szabo","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/5\/1153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:49Z","timestamp":1760124769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/5\/1153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["v15051153"],"URL":"https:\/\/doi.org\/10.3390\/v15051153","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}